Drug: |
Belzutifan |
|||
---|---|---|---|---|
Trial: |
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) |
|||
Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Recruiting |
MD Anderson Cancer Center1505 Holcombe Blvd. |
Principal Investigator: |
|
---|---|
Contact: |
Study Coordinator 713-792-2841 |
Activation Status of this Site: |
Active |
Notes about this Site: |
|
MD Anderson Cancer Center Website: |
http://www.mdanderson.org/Cancer_Pro/CS_Resources/display.cfm?id=562561A1-751F-11D4-AEBD00508BDCCE3A&method=displayFull |
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.